PT  - JOURNAL ARTICLE
AU  - Michael Jochen Marco Fischer
AU  - Stanislav Koulchitsky
AU  - Karl Messlinger
TI  - The Nonpeptide Calcitonin Gene-Related Peptide Receptor Antagonist BIBN4096BS Lowers the Activity of Neurons with Meningeal Input in the Rat Spinal Trigeminal Nucleus
AID  - 10.1523/JNEUROSCI.0869-05.2005
DP  - 2005 Jun 22
TA  - The Journal of Neuroscience
PG  - 5877--5883
VI  - 25
IP  - 25
4099  - http://www.jneurosci.org/content/25/25/5877.short
4100  - http://www.jneurosci.org/content/25/25/5877.full
SO  - J. Neurosci.2005 Jun 22; 25
AB  - Calcitonin gene-related peptide (CGRP) has been suggested to play a major role in the pathogenesis of migraines and other primary headaches. CGRP may be involved in the control of neuronal activity in the spinal trigeminal nucleus (STN), which integrates nociceptive afferent inputs from trigeminal tissues, including intracranial afferents. The activity of STN neurons is thought to reflect the activity of central trigeminal nociceptive pathways causing facial pain and headaches in humans. In a rat model of meningeal nociception, single neuronal activity in the STN was recorded. All units had receptive fields located in the exposed parietal dura mater. Heat and cold stimuli were repetitively applied to the dura in a fixed pattern of ramps and steps. The nonpeptide CGRP receptor antagonist BIBN4096BS was topically applied onto the exposed dura or infused intravenously. BIBN4096BS (300 μg/kg, i.v.) reduced spontaneous activity by ∼30%, the additional dose of 900 μg/kg intravenously by ∼50% of the initial activity, whereas saline had no effect. The activity evoked by heat ramps was also reduced after BIBN4096BS (900 μg/kg, i.v.) by ∼50%. Topical administration of BIBN4096BS (1 mm) did not significantly change the spontaneous neuronal activity within 15 min. We conclude that the endogenous release of CGRP significantly contributes to the maintenance of spontaneous activity in STN neurons. Blockade of CGRP receptors, possibly at central and peripheral sites, may therefore be an effective way to decrease nociceptive transmission. This may offer a new therapeutic strategy for the treatment of facial pain and primary headaches.